StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) company profile

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

About Myriad Genetics

In Vitro & In Vivo Diagnostic Substances, SIC 2835

Myriad Genetics is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests to assess disease risk, guide treatment decisions, and provide prenatal insights. The business focuses on three main segments: oncology, women's health, and mental health. Key products include hereditary cancer panels such as MyRisk, companion diagnostics like BRACAnalysis CDx and MyChoice CDx, tumor profiling assays including Prolaris, prenatal screens such as Prequel and Foresight, and pharmacogenomic tests like GeneSight. Its customers include patients, healthcare providers, health systems, and biopharmaceutical partners.

The company employs approximately 2,700 full-time equivalent staff and operates next-generation laboratory facilities. It sells its products directly through commercial teams in the United States and Japan, while serving broader international markets across Europe and the Asia-Pacific region via indirect channels and partnerships. The provided text does not disclose the company's headquarters location.

Summary of the business section of Myriad Genetics's latest annual report, written by StockData.

Company profile

Company

Legal name
Myriad Genetics Inc
Founded
1992
Headquarters
Salt Lake City, UT
Address
322 North 2200 West 84116
Phone
(801) 584-3600
Website
myriad.com
Employees
2,700, Dec 31, 2025
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Salt Lake City, Utah

Stock & identifiers

Ticker
MYGN
Exchange
Nasdaq
IPO date
Oct 6, 1995
Shares outstanding
96M, Jul 28, 2026
Public float
$494.05M, Jun 30, 2025
Filer category
Accelerated filer
Stock splits
2-for-1, Mar 26, 2009; 2-for-1, Sep 12, 2000
SEC CIK
899923
CUSIP
62855J104
ISIN
US62855J1043
FIGI
BBG000D9H9F1
Share class FIGI
BBG001S86FS9
LEI
52990044IHUOUMETT163
EIN
87-0494517

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Samraat S. RahaPresident and CEO, Director1,068,083
Paul J. DiazPresident and CEO, Director891,844
Vishal SikriEVP, Commercial93,493
Jennifer Lynne FoxChief Legal & Corp Strategy345,334
Raj JampaChief Technology Officer251,889
Benjamin Richard WheelerChief Financial Officer287,193
Mark VerrattiChief Operating Officer629,646
Dale MuzzeyChief Scientific Officer326,310
Shereen SolaimanChief People Officer267,801
Brian J. DonnellyChief Commercial Officer573,363
Kevin Richard HaasChief Technology Officer188,404
Margaret AnconaEVP, Strategy & Transformation127,726
Natalie MunkChief Accounting Officer45,167
Scott J. LefflerChief Financial Officer218,393
Daniel SkovronskyDirector195,507
Rashmi KumarDirector171,889
Mark Steven DavisDirector106,665
S. Louise PhanstielDirector374,771
Paul BisaroDirector157,142
Heinrich DreismannDirector231,145
Colleen F. ReitanDirector152,030
Lee Nisley NewcomerDirector191,842

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Paul JDiaz
$688.64K-$7.78M$2.86M$31$125
FY2025
Samraat S.Raha
$5.69M$2.52M$2.86M$31$125
FY2024$13.63M$7.21M$3.48M$69$93
FY2023$12.11M$14.20M$4.14M$97$94
FY2022$11.39M-$4.48M$2.67M$73$90
FY2021$12.79M$29.79M$2.48M$140$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Samraat S. Raha
President and Chief Executive Officer
$856.90K–$3.99M$814.66K$25.45K$5.69M+30%
Paul J. Diaz
Former President and Chief Executive Officer
$418.10K–––$270.53K$688.64K-95%
Benjamin R. Wheeler
Chief Financial Officer
$408.49K–$759.23K$325.42K$14.75K$1.51M–
Scott J. Leffler
Former Chief Financial Officer
$393.80K–$1.07M–$1.28M$2.74M-56%
Mark S. Verratti
Chief Operating Officer
$622.88K–$2.06M$438.32K$25.98K$3.15M-15%
Brian J. Donnelly
Chief Commercial Officer
$350.00K$450.00K$4.80M$371.91K$26.34K$6.00M–
Dale Muzzey, Ph.D.
Chief Scientific Officer
$506.40K–$1.12M$221.68K$13.78K$1.86M-38%
Margaret Ancona
Former EVP, Strategy and Transformation
$330.85K–$800.75K–$763.56K$1.90M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 2,700 full-time equivalent employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?